Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis

References

• Patient Registry Annual Data Report 2009. Cystic Fibrosis Foundation, 2009. Available at: http://www.cff.org/UploadedFiles/research/ClinicalResearch/Patient-Registry-Report-2009.pdf [Last accessed 26 September 2011]
   Google Scholar
• Brennan AL, Geddes DM. Cystic fibrosis. Curr Opin Infect Dis 2002;15:175-82
   PubMed Web of Science ®Google Scholar
• Geller DE, Rubin BK. Respiratory care and cystic fibrosis. Respir Care 2009;54:796-800
   PubMed Web of Science ®Google Scholar
• Zemanick ET, Harris JK, Conway S, et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros 2010;9:1-16
   PubMed Web of Science ®Google Scholar
• Braccini G, Festini F, Boni V, et al. The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Chemother 2009;21:188-92
   PubMed Web of Science ®Google Scholar
• Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 2009;54:628-38
   PubMed Web of Science ®Google Scholar
• Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010;5:1663-74
   PubMed Web of Science ®Google Scholar
• Lillquist YP, Cho E, Davidson AG. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. J Cyst Fibros 2011;10:175-80
   PubMed Web of Science ®Google Scholar
• Lee TW. Eradication of early Pseudomonas infection in cystic fibrosis. Chron Respir Dis 2009;6:99-107
   PubMedGoogle Scholar
• Ratjen F, Munck A, Kho P, et al. Treatment with early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-91
   PubMed Web of Science ®Google Scholar
• Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974–1995). Pediatr Pulmonol 1999;28:159-66
   PubMed Web of Science ®Google Scholar
• Starner TD, McCray PB Jr. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med 2005;143:816-22
   PubMed Web of Science ®Google Scholar
• Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-61
   PubMed Web of Science ®Google Scholar
• Ballmann M, Rabsch P, von der Hardt H. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998;53:732-7
   PubMed Web of Science ®Google Scholar
• Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54:658-69
   PubMed Web of Science ®Google Scholar
• Foweraker JE, Laughton CR, Brown DF, et al. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother 2009;53:4809-15
   PubMed Web of Science ®Google Scholar
• Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paed Respir 2010;11:177-8
   PubMed Web of Science ®Google Scholar
• Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005;4(Suppl 2):49-54
   PubMedGoogle Scholar
• Döring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91
   PubMedGoogle Scholar
• Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Pediatr Pulmonol 1998;25:88-92
   PubMed Web of Science ®Google Scholar
• Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69
   PubMed Web of Science ®Google Scholar
• Döring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-67
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30
   PubMed Web of Science ®Google Scholar
• McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-8
   PubMed Web of Science ®Google Scholar
• Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121-34
   PubMed Web of Science ®Google Scholar
• Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5
   PubMed Web of Science ®Google Scholar
• Lee TW, Brownlee KG, Denton M, et al. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004;37:104-10
   PubMed Web of Science ®Google Scholar
• Ho S-A, Lee TWR, Denton M, et al. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J Cystic Fibrosis 2009;8:43-6
   PubMed Web of Science ®Google Scholar
• Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med 2002;95(Suppl 41):22-6
   PubMed Web of Science ®Google Scholar
• Jones AM, Govan JRW, Doherty CJ, et al. Increased treatment requirements of cystic fibrosis patients who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002;57:924-5
   PubMed Web of Science ®Google Scholar
• Hayes D Jr, West SE, Rock MJ, et al. Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypes. Pediatr Pulmonol 2010;45:708-16
   PubMed Web of Science ®Google Scholar
• McKay KO, Cooper PJ, van Asperen PP. Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa. J Cyst Fibros 2009;8:400-4
   PubMed Web of Science ®Google Scholar
• Jones AM, Dodd ME, Govan JRW, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a Cystic Fibrosis Center. Am J Respir Crit Care Med 2005;171:257-60
   PubMed Web of Science ®Google Scholar
• Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005;26:458-61
   PubMed Web of Science ®Google Scholar
• Ratjen F, Brockhaus F, Angyalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 2009:8:361-9
   PubMed Web of Science ®Google Scholar
• Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7:523-30
   PubMed Web of Science ®Google Scholar
• Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC Clinical Trial and Observational Study. Contemp Clin Trials 2009;30:256-68
   PubMed Web of Science ®Google Scholar
• Gilligan PH. Is there value in susceptibility testing of Pseudomonas aeruginosa causing chronic infection in patients with cystic fibrosis? Expert Rev Anti Infect Ther 2006;4:711-15
   PubMedGoogle Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-51
   PubMed Web of Science ®Google Scholar
• Brown SMN, Balfour-Lynn IM. Duration of intravenous antibiotic treatment for respiratory exacerbations in children with cystic fibrosis. Arch Dis Child 2010;95:568
   PubMed Web of Science ®Google Scholar
• Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8
   PubMed Web of Science ®Google Scholar
• Moskowitz SM, Silva SJ, Mayer-Hamblett N, et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008;43:874-81
   PubMed Web of Science ®Google Scholar
• Stephens D, Garey N, Isles A, et al. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 1983;2:209-11
   PubMedGoogle Scholar
• Schaad UB, Wedgwood-Krucko J, Suter S, et al. Efficacy of inhaled amikacin as an adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987;111:599-605
   PubMed Web of Science ®Google Scholar
• Semsarian C. Efficacy of inhaled tobramycin in cystic fibrosis. J Paediatr Child Health 1990;26:110-11
   PubMed Web of Science ®Google Scholar
• Conway SP. Nebulized antibiotic therapy: the evidence. Chron Respir Dis 2005;2:35-41
   PubMedGoogle Scholar
• Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;CD001021
   PubMed Web of Science ®Google Scholar
• Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-13
   PubMed Web of Science ®Google Scholar
• MacLeod DL, Nelson LE, Shawar RM, et al. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis 2000;181:1180-4
   PubMed Web of Science ®Google Scholar
• Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8:295-315
   PubMed Web of Science ®Google Scholar
• TOBI (tobramycin). Prescribing information. Available at: http://www.tobitime.com/info/tools/prescribing.jsp [Last accessed 26 September 2011]
   Google Scholar
• Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63
   PubMed Web of Science ®Google Scholar
• Quittner AL, Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002;33:269-76
   PubMed Web of Science ®Google Scholar
• Stass H, Baumann-Noss S, Delesen H, et al. Pharmacokinetics of ciprofloxacin Pulmo-Sphere inhalational powder. J Cyst Fibros 2008;7:S26. Abstract 103
   Google Scholar
• Westerman EM, De Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros 2007;6:284-92
   PubMed Web of Science ®Google Scholar
• Westerman EM, de Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm 2007;335:41-5
   PubMed Web of Science ®Google Scholar
• Westerman EM, Heijerman HG, Frijlink HW. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin Drug Deliv 2007;4:91-4
   PubMed Web of Science ®Google Scholar
• Wilson J, Moorehead L, Montgomery B. A phase 1 open label trial to assess the safety and tolerability of fosfomycin/tobramycin for inhalation (FTI) in subjects with cystic fibrosis (CF) or bronchiectasis (BE). Pediatr Pulmonol 2008(Suppl 31):320-1. Abstract 337
   Google Scholar
• Geller DE, Flume P, Schwab R, et al. A Phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients. Pediatr Pulmonol 2008(Suppl 31):315. Abstract 321
   Google Scholar
• Griffith DC, Hansen C, Pressler T, et al. Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications. J Cyst Fibros 2008;7:S26. Abstract 104
   Google Scholar
• Bruinenberg P, Otulana B, Blanchard J, et al. The effect of once-a day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization. Pediatr Pulmonol 2008(Suppl 31):344. Abstract 401
   Google Scholar
• Dupont L, Minic P, Fustik S, et al. A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Cyst Fibros 2008;7:S26. Abstract 102
   Google Scholar
• Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53:3847-54
   PubMed Web of Science ®Google Scholar
• Hubert D, Leroyb S, Nove-Josserand R, et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis. J Cystic Fibrosis 2009;8:332-7
   PubMed Web of Science ®Google Scholar
• Denk OL, Coates AL, Leung K, et al. Lung delivery of a new tobramycin nebuliser solution (150 mg/1.5 mL) by an investigational eFlow nebuliser is equivalent to TOBI but in a fraction of time. J Cystic Fibros 2009;8:S66
   PubMed Web of Science ®Google Scholar
• Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8
   PubMed Web of Science ®Google Scholar
• Hodson ME, Gallagher CG, Govan JRW. A randomized clinical trial of nebulized tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-64
   PubMed Web of Science ®Google Scholar
• Hagerman JK, Knechtel SA, Klepser ME. Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature. Expert Opin Pharmacother 2007;8:467-75
   PubMed Web of Science ®Google Scholar
• Morosini MI, Garcià-Castillo M, Loza E, et al. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range etest strips. J Clin Microbiol 2005;43:4480-5
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009;8:91-6
   PubMed Web of Science ®Google Scholar
• Conway SP, Pond MN, Hamnett T, et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996;51:29-33
   PubMed Web of Science ®Google Scholar
• Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006;31:846-58
   PubMed Web of Science ®Google Scholar
• Daniels T. Physiotherapeutic management strategies for the treatment of cystic fibrosis in adults. J Multidiscip Healthc 2010;3:201-12
   PubMedGoogle Scholar
• Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011;140:425-32
   PubMed Web of Science ®Google Scholar
• Abbott J, Havermans T, Hart A. Adherence to the medical regimen: clinical implications of new findings. Curr Opin Pulm Med 2009; 15:597-603
   PubMed Web of Science ®Google Scholar
• Latchford G, Duff A, Quinn J, et al. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 2009;75:141-4
   PubMed Web of Science ®Google Scholar
• Abbott J, Dodd M, Bilton D, et al. Treatment compliance in adults with cystic fibrosis. Thorax 1994;49:115-20
   PubMed Web of Science ®Google Scholar
• Poole Arcangelo V, Peterson AM. Principles of pharmacotherapy in pediatrics. In: Pharmacotherapeutics for Advanced Practice: A Practical Approach, 2nd edn. Lippincott Williams & Wilkins, 2006:47
   Google Scholar
• Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10:54-61
   PubMed Web of Science ®Google Scholar
• O’Malley CA. Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist. Respir Care 2009;54:641-55
   PubMed Web of Science ®Google Scholar
• Saiman L, Siegel J, and the Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003;24:S6-52
   PubMed Web of Science ®Google Scholar
• Blau H, Mussaffi H, Mei Zahav M, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007;33:491-5
   PubMed Web of Science ®Google Scholar
• Lester MK, Flume PA, Gray SL, et al. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care 2004;49:1504-8
   PubMedGoogle Scholar
• Rosenfeld M, Emerson J, Astley S, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998;132:125-31
   PubMed Web of Science ®Google Scholar
• Geller DE, Weers J, Heuerding H. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J Aero Pulm Med Drug Deliv 2011;24:175-82
   PubMed Web of Science ®Google Scholar
• Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223-32
   PubMed Web of Science ®Google Scholar
• Konstan MW, Geller DE, Minić P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46:230-8
   Google Scholar
• Haynes A, Nakamura J, Heng C, et al. Aerosol performance of tobramycin inhalation powder. In Dalby RN, Byron PR, Peart J, et al (eds) Respiratory Drug Delivery 2010. Davis Healthcare Intl Publ, 2010;3:701-6
   Google Scholar
• MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009;64:829-36
   PubMed Web of Science ®Google Scholar
• Jaffé A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998;351:420
   PubMed Web of Science ®Google Scholar
• Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615
   PubMed Web of Science ®Google Scholar
• Steinkamp G, Schmitt-Grohe S, Döring G, et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008;102:1643-53
   PubMed Web of Science ®Google Scholar
• Riethmüller J, Anthonysamy J, Serra E, et al. Therapeutic efficacy and safety of amitryptaline in cystic fibrosis. Cell Physiol Biochem 2009;24:65-72
   PubMed Web of Science ®Google Scholar
• Zamorano L, Juan C, Fernández-Olmos A, et al. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. Antimicrob Agents Chemother 2010;54:121-7
   Web of Science ®Google Scholar